Skip to main content
. 2017 Jul 28;8(40):68095–68107. doi: 10.18632/oncotarget.19677

Figure 1. Diagram showing our bio-informatics approach to lung cancer biomarker discovery.

Figure 1

For this analysis, we chose to focus on non-small lung cancer patients, with negative surgical margins, and 10-years of follow-up data (N = 726). In this context, we evaluated the prognostic value of mitochondrial markers for predicting overall survival, time to first progression, and post-progression survival.